Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (348)	12/28/2010 9:44:16 AM
From: John McCarthy	Respond to of 421

Hi Arthur That was great news ...... I heard the ALIM cc and have dumbed it down to ..... If you use Iluvien - * you WILL get cataracks * and the FDA is trying to see how often. I am hanging (not selling) and while you might not agree with or follow my logic hope it falls to below $3.00 ... even $2.00 ... would then like the (risk versus reward thingie) and put in for JUST a few more ..... I don't think the Mod. ARTS or ARTS come into play - just Intent to Treat BUT - if CATARACKS develop continuoulsy over the course timeline of treatment - months 18 --> 36 we is gonna get booted down the block and become a non-event historical footnote in biotech ... So - dead money for 6 months and then we see ... regards John

To: Arthur Radley who wrote (348)	1/27/2011 9:42:40 AM
From: John McCarthy	Read Replies (1) \| Respond to of 421

Hi Arthur Not sure if your still in but .... Alimera Sciences to Hold Conference Call to Discuss Results From the Final Readout of the FAME(TM) Study of ILUVIEN(R) ATLANTA, Jan. 27, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM - News) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release data from the final readout of the FAME Study after the market close on Thursday, February 3, 2011. The FAME Study consists of two 36-month Phase 3 pivotal clinical trials to assess the safety and efficacy of ILUVIEN(R) in the treatment of diabetic macular edema (DME). finance.yahoo.com EDIT from a bad memory --- I think the 1st week in Feb was when Alimera had hoped to meet with the FDA